712610login-checkCareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance |
AUGUST, 02, 2023
HeartCare Combines Testing Using Both AlloMap Gene Expression Profiling and AlloSure Donor-Derived Cell-Free DNA
BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Medicare coverage for HeartCare, a multimodality testing service that includes both AlloMap® Heart and AlloSure® Heart, in a given patient encounter, for heart transplant surveillance. Coverage is effective April 1, 2023. AlloMap Heart and AlloSure Heart are also covered by Medicare individually. Read the complete press release on CareDx.com.
712610login-checkCareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance |